Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
Eisai Inc.
Stanford University
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Hoffmann-La Roche
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
Incyte Corporation
INSYS Therapeutics Inc
Altor BioScience